MX2021009722A - Anticuerpos anti-trem2 y metodos para utilizarlos. - Google Patents
Anticuerpos anti-trem2 y metodos para utilizarlos.Info
- Publication number
- MX2021009722A MX2021009722A MX2021009722A MX2021009722A MX2021009722A MX 2021009722 A MX2021009722 A MX 2021009722A MX 2021009722 A MX2021009722 A MX 2021009722A MX 2021009722 A MX2021009722 A MX 2021009722A MX 2021009722 A MX2021009722 A MX 2021009722A
- Authority
- MX
- Mexico
- Prior art keywords
- trem2
- methods
- trem2 antibodies
- antibodies
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 | |
| PCT/US2020/019093 WO2020172450A1 (en) | 2019-02-20 | 2020-02-20 | Anti-trem2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009722A true MX2021009722A (es) | 2021-09-14 |
Family
ID=69844940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009722A MX2021009722A (es) | 2019-02-20 | 2020-02-20 | Anticuerpos anti-trem2 y metodos para utilizarlos. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20220073609A1 (https=) |
| EP (1) | EP3927743A1 (https=) |
| JP (2) | JP7543290B2 (https=) |
| KR (1) | KR20210135518A (https=) |
| CN (1) | CN113614110B (https=) |
| AR (1) | AR118144A1 (https=) |
| AU (1) | AU2020226754A1 (https=) |
| BR (1) | BR112021015656A2 (https=) |
| CA (1) | CA3130086A1 (https=) |
| CL (1) | CL2021002206A1 (https=) |
| CO (1) | CO2021012230A2 (https=) |
| EA (1) | EA202192294A1 (https=) |
| EC (1) | ECSP21069105A (https=) |
| IL (1) | IL285651A (https=) |
| MA (1) | MA55025A (https=) |
| MX (1) | MX2021009722A (https=) |
| PE (1) | PE20211979A1 (https=) |
| PH (1) | PH12021552002A1 (https=) |
| SG (1) | SG11202108734VA (https=) |
| TW (1) | TWI879756B (https=) |
| WO (2) | WO2020172457A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| SG11202104352XA (en) * | 2018-12-18 | 2021-05-28 | Boehringer Ingelheim Io Canada Inc | Flt3 agonist antibodies and uses thereof |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| AU2022273303A1 (en) * | 2021-05-14 | 2023-11-02 | Genentech, Inc. | Agonists of trem2 |
| WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2024160736A1 (en) | 2023-01-30 | 2024-08-08 | Isar Bioscience Gmbh | Human anti-trem2 antibody for treating neurodegenerative disorders |
| KR20260051042A (ko) | 2023-08-09 | 2026-04-15 | 에프. 호프만-라 로슈 아게 | 단일 및 다중특이성 항-trem2 항체, 그 방법 및 용도 |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025046298A2 (en) | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| WO2025106361A1 (en) * | 2023-11-15 | 2025-05-22 | Merck Sharp & Dohme Llc | Human nectin-4 binders |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| CA2746470A1 (en) | 2009-01-06 | 2010-07-15 | Raymond-David Pridmore | Processing of macronutrients |
| TWI541021B (zh) | 2009-03-05 | 2016-07-11 | 艾伯維有限公司 | Ｉｌ－１７結合蛋白 |
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| JPWO2012176779A1 (ja) * | 2011-06-20 | 2015-02-23 | 協和発酵キリン株式会社 | 抗ｅｒｂＢ３抗体 |
| BR112015027313A2 (pt) | 2013-04-29 | 2017-09-26 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado |
| WO2015033223A2 (en) | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| CN105218669A (zh) | 2014-06-10 | 2016-01-06 | 河北翰林生物科技有限公司 | 制备抗人r47h-trem2突变体的人单克隆抗体的方法 |
| CA2955086A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| CA2961950A1 (en) | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| EP3973980A1 (en) * | 2015-03-31 | 2022-03-30 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a trimeric tnf family ligand |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2017147509A1 (en) | 2016-02-25 | 2017-08-31 | Marco Colonna | Compositions comprising trem2 and methods of use thereof |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CN109641961A (zh) | 2016-07-22 | 2019-04-16 | 德国神经退行性疾病研究中心 | Trem2切割调节剂及其用途 |
| CA3048224A1 (en) | 2016-12-23 | 2018-06-28 | Bluefin Biomedicine, Inc. | Anti-sez6l2 antibodies and antibody drug conjugates |
| EP3570883A2 (en) | 2017-01-17 | 2019-11-27 | Yeda Research and Development Co. Ltd | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| BR112020001060A2 (pt) | 2017-07-27 | 2020-07-14 | Novartis Ag | variantes de trem2 resistentes a shedase |
| DK3601358T5 (da) | 2017-08-03 | 2024-09-02 | Alector Llc | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf |
| EP3665194A4 (en) | 2017-08-10 | 2021-07-07 | Denali Therapeutics Inc. | AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS |
| WO2019055841A1 (en) | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| US20210186917A1 (en) | 2017-10-17 | 2021-06-24 | The Translational Genomics Research Institute | Trem2 agonists for the stimulation of microglia and methods of identification |
| WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| AU2018383709B2 (en) | 2017-12-12 | 2025-09-11 | Pionyr Immunotherapeutics, Inc. | Anti-TREM2 antibodies and related methods |
| TW201934573A (zh) | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
| WO2019246071A1 (en) | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| WO2020037150A2 (en) | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| JP2021534220A (ja) | 2018-08-22 | 2021-12-09 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
| CA3111569A1 (en) | 2018-09-11 | 2020-03-19 | Washington University | Anti-trem-2 agonist antibodies |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| KR102156165B1 (ko) | 2018-10-29 | 2020-09-15 | 재단법인대구경북과학기술원 | 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| CA3120970A1 (en) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Methods for treating dysregulated lipid metabolism |
| US20220025065A1 (en) | 2018-12-10 | 2022-01-27 | Denali Therapeutics Inc. | Lysosomal storage disorder biomarkers and methods of use thereof |
| US12351629B2 (en) | 2018-12-10 | 2025-07-08 | Mor Research Applications Ltd. | TREM2 antibodies and uses thereof |
| KR20210104079A (ko) | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
| CA3134538A1 (en) | 2019-04-03 | 2020-10-08 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| PH12022551598A1 (en) | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| WO2021146256A1 (en) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| WO2021158986A1 (en) | 2020-02-07 | 2021-08-12 | Denali Therapeutics Inc. | Methods for the treatment of hunter syndrome |
| AU2021224200A1 (en) | 2020-02-19 | 2022-09-08 | Denali Therapeutics Inc. | Engineered anti-HER2 bispecific proteins |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
-
2020
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/pt unknown
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/en not_active Ceased
- 2020-02-20 PH PH1/2021/552002A patent/PH12021552002A1/en unknown
- 2020-02-20 CN CN202080015804.2A patent/CN113614110B/zh active Active
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/ko not_active Ceased
- 2020-02-20 CA CA3130086A patent/CA3130086A1/en active Pending
- 2020-02-20 TW TW109105560A patent/TWI879756B/zh active
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/es unknown
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
- 2020-02-20 MA MA055025A patent/MA55025A/fr unknown
- 2020-02-20 JP JP2021548668A patent/JP7543290B2/ja active Active
- 2020-02-20 AR ARP200100461A patent/AR118144A1/es unknown
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/en not_active Ceased
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/es unknown
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/en active Pending
- 2020-02-20 EA EA202192294A patent/EA202192294A1/ru unknown
-
2021
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en not_active Abandoned
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/402,986 patent/US12240902B2/en active Active
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/es unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/es unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/es unknown
-
2024
- 2024-08-21 JP JP2024139367A patent/JP7842822B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3927743A1 (en) | 2021-12-29 |
| US20220119522A1 (en) | 2022-04-21 |
| KR20210135518A (ko) | 2021-11-15 |
| WO2020172457A1 (en) | 2020-08-27 |
| AR118144A1 (es) | 2021-09-22 |
| JP2024164116A (ja) | 2024-11-26 |
| JP7543290B2 (ja) | 2024-09-02 |
| JP7842822B2 (ja) | 2026-04-08 |
| ECSP21069105A (es) | 2021-11-18 |
| US20220073609A1 (en) | 2022-03-10 |
| WO2020172450A1 (en) | 2020-08-27 |
| CA3130086A1 (en) | 2020-08-27 |
| JP2022520868A (ja) | 2022-04-01 |
| PH12021552002A1 (en) | 2022-09-19 |
| BR112021015656A2 (pt) | 2021-10-05 |
| CL2021002206A1 (es) | 2022-04-22 |
| AU2020226754A1 (en) | 2021-09-16 |
| SG11202108734VA (en) | 2021-09-29 |
| TWI879756B (zh) | 2025-04-11 |
| IL285651A (en) | 2021-09-30 |
| TW202045543A (zh) | 2020-12-16 |
| EA202192294A1 (ru) | 2021-12-24 |
| CO2021012230A2 (es) | 2021-09-30 |
| CN113614110B (zh) | 2025-03-25 |
| PE20211979A1 (es) | 2021-10-05 |
| US12240902B2 (en) | 2025-03-04 |
| CN113614110A (zh) | 2021-11-05 |
| MA55025A (fr) | 2021-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009722A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| CO2022009744A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
| CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
| CO2021006911A2 (es) | Anticuerpos biespecíficos anti-pd-l1/anti-4-1bb y usos de los mismos | |
| CL2022001886A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| CO2022009737A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| BR112021021645A2 (pt) | Anticorpos anti-hvem e uso dos mesmos. | |
| MX2021004284A (es) | Anticuerpos anti-npr1 y usos de los mismos. | |
| AR122930A1 (es) | Anticuerpos de pre-direccionamiento y métodos de uso | |
| MX2025005542A (es) | Moléculas antagonistas de fcrn y métodos de uso de estas | |
| CO2019009035A2 (es) | Proteínas de unión al receptor de glucagón y métodos para usarlas | |
| CL2025002112A1 (es) | Anticuerpo anti-npr1; método de producción; y su uso. | |
| JOP20250298A1 (ar) | تركيبات جسم مضاد لإنتيجرين α4β7 وطرق استخدامها | |
| ECSP22056627A (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| JOP20240021A1 (ar) | الأجسام المضادة لمستقبل إنترلوكين-4 ألفا البشري | |
| MX2020008114A (es) | Cuantificacion y modelado de atributos de calidad de anticuerpos monoclonales terapeuticos. | |
| CL2022000752A1 (es) | Molécula de unión específica para lif y uso de la misma | |
| MX2021012848A (es) | Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn. | |
| EA202192396A1 (ru) | Способы и композиции для лечения рака | |
| CO2025010348A2 (es) | Anticuerpos anti-pdl1 y métodos de uso | |
| AR098796A1 (es) | Anticuerpos anti-cd3 y métodos de uso | |
| AR098915A1 (es) | ANTICUERPOS QUE SE UNEN A b-KLOTHO (KLB) Y MÉTODOS DE USO |